APOE and Cognitive impairment: In the study, we set out to integrate with new evidence the original RNF219 findings (Rhinn et al., 2013) and evaluated whether APOE-ε4 and RNF219/G work in synergy or independently to affect the behavioral or cognitive features of patients affected by mild cognitive impairment (MCI) or AD.